Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CELUNASDAQ:GALTNASDAQ:MNOVNASDAQ:VERU On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELUCelularity$2.01+14.2%$1.87$1.00▼$5.22$42.15M0.76336,773 shs166,425 shsGALTGalectin Therapeutics$2.48+2.5%$1.48$0.73▼$3.90$153.17M0.54408,781 shs975,728 shsMNOVMediciNova$1.31+1.6%$1.42$1.12▼$2.55$63.27M0.4236,425 shs17,177 shsVERUVeru$0.62-0.5%$0.55$0.45▼$1.42$91.34M-0.81.91 million shs910,541 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELUCelularity+14.20%+14.20%-12.23%-6.51%-34.10%GALTGalectin Therapeutics+2.48%+66.44%+93.75%+40.11%+5.98%MNOVMediciNova+1.55%-1.50%-7.09%-10.88%-5.76%VERUVeru-0.50%+3.37%+24.37%+19.81%-20.59%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCELUCelularity0.0781 of 5 stars0.02.00.00.00.01.70.0GALTGalectin Therapeutics1.6278 of 5 stars3.50.00.00.03.11.70.0MNOVMediciNova2.4073 of 5 stars3.83.00.00.02.70.80.0VERUVeru1.9148 of 5 stars3.51.00.00.03.01.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCELUCelularity 0.00N/AN/AN/AGALTGalectin Therapeutics 3.00Buy$6.00141.94% UpsideMNOVMediciNova 3.50Strong Buy$7.00434.35% UpsideVERUVeru 3.00Buy$4.00545.16% UpsideCurrent Analyst Ratings BreakdownLatest MNOV, CELU, GALT, and VERU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025GALTGalectin TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.006/16/2025MNOVMediciNovaB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy ➝ Strong-Buy$6.00 ➝ $5.004/9/2025MNOVMediciNovaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/2/2025GALTGalectin TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCELUCelularity$54.22M0.89N/AN/A$0.37 per share5.43GALTGalectin TherapeuticsN/AN/AN/AN/A($1.68) per shareN/AMNOVMediciNova$1M64.26N/AN/A$1.07 per share1.22VERUVeru$16.89M5.38N/AN/A$0.22 per share2.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCELUCelularity-$57.89M-$2.65N/A∞N/A-106.77%-271.88%-42.82%7/28/2025 (Estimated)GALTGalectin Therapeutics-$47.05M-$0.72N/AN/AN/AN/AN/A-216.05%8/12/2025 (Estimated)MNOVMediciNova-$11.04M-$0.23N/AN/AN/AN/A-20.77%-19.68%8/6/2025 (Estimated)VERUVeru-$37.80M-$0.24N/AN/AN/A-223.85%-128.51%-76.51%8/6/2025 (Estimated)Latest MNOV, CELU, GALT, and VERU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025GALTGalectin Therapeutics-$0.20-$0.15+$0.05-$0.15N/AN/A5/13/2025Q1 2025MNOVMediciNova-$0.14-$0.06+$0.08-$0.06N/AN/A5/8/2025Q4 2024CELUCelularity-$1.50-$0.59+$0.91-$0.59$5.20 million$18.13 million5/8/2025Q2 2025VERUVeru-$0.06-$0.05+$0.01-$0.05$0.73 millionN/A3/31/2025Q4 2024GALTGalectin Therapeutics-$0.16-$0.19-$0.03-$0.19N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCELUCelularityN/AN/AN/AN/AN/AGALTGalectin TherapeuticsN/AN/AN/AN/AN/AMNOVMediciNovaN/AN/AN/AN/AN/AVERUVeruN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCELUCelularity4.070.380.28GALTGalectin TherapeuticsN/A0.080.08MNOVMediciNovaN/A17.6617.66VERUVeruN/A3.803.80Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCELUCelularity19.02%GALTGalectin Therapeutics11.68%MNOVMediciNova9.90%VERUVeru47.16%Insider OwnershipCompanyInsider OwnershipCELUCelularity22.10%GALTGalectin Therapeutics50.10%MNOVMediciNova13.60%VERUVeru15.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCELUCelularity22023.95 million18.66 millionOptionableGALTGalectin Therapeutics963.29 million31.58 millionOptionableMNOVMediciNova1049.05 million42.38 millionOptionableVERUVeru230146.58 million124.30 millionOptionableMNOV, CELU, GALT, and VERU HeadlinesRecent News About These CompaniesOne Veru Insider Raised Stake By 150% In Previous YearJune 22 at 9:22 AM | finance.yahoo.comScholar Rock drug preserves muscle in obesity trialJune 18, 2025 | yahoo.comInvestors Buy High Volume of Veru Put Options (NASDAQ:VERU)June 18, 2025 | americanbankingnews.comTraders Buy High Volume of Put Options on Veru (NASDAQ:VERU)June 17, 2025 | marketbeat.comVeru (NASDAQ:VERU) Stock Crosses Below 200-Day Moving Average - Here's WhyJune 17, 2025 | marketbeat.comVeru Inc. to Engage with Investors at BTIG Obesity Health Forum on June 18, 2025June 11, 2025 | quiverquant.comVeru to Participate in the Virtual BTIG Obesity Health ForumJune 11, 2025 | globenewswire.comBeyond Meat, Plby among consumer staple names set to join Russell Microcap Index, Veru, Vital Farms to leaveMay 30, 2025 | seekingalpha.comVeru’s obesity drug roughly as safe as Wegovy; Keros’ board fightMay 28, 2025 | endpts.comMuscle-sparing obesity drug safe for Phase 3 trial, Veru saysMay 28, 2025 | yahoo.comVeru Inc. Announce Positive Topline Safety Data from Phase 2b QUALITY Study of Enobosarm Combined with SemaglutideMay 28, 2025 | quiverquant.comVeru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide AloneMay 28, 2025 | globenewswire.comVeru: Saving Muscle Mass Amidst The GLP-1 Drug BoomMay 26, 2025 | seekingalpha.comYoungsters at Dunstable school hear about the dangers of knife crimeMay 22, 2025 | msn.comVeru Inc.: Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program ProgressMay 8, 2025 | finanznachrichten.deVeru signals Q3 2025 regulatory clarity for enobosarm Phase 3 trialMay 8, 2025 | msn.comVeru Inc. (VERU) Q2 2025 Earnings Call TranscriptMay 8, 2025 | seekingalpha.comJTC Team, LLC: JTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s Enobosarm Taking GLP-1 Weight Loss to Next LevelMay 8, 2025 | finanznachrichten.deJTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s (NASDAQ:VERU) Enobosarm Taking GLP-1 Weight Loss to Next LevelMay 8, 2025 | accessnewswire.comVeru Participates in a Virtual Investor KOL Connect SegmentMay 8, 2025 | globenewswire.comVeru Inc. Announces Upcoming Safety Data and Phase 2b Study Updates for Enobosarm in Weight Management TreatmentMay 8, 2025 | quiverquant.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMNOV, CELU, GALT, and VERU Company DescriptionsCelularity NASDAQ:CELU$2.01 +0.25 (+14.20%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$2.04 +0.03 (+1.49%) As of 06/23/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.Galectin Therapeutics NASDAQ:GALT$2.48 +0.06 (+2.48%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$2.34 -0.14 (-5.60%) As of 06/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.MediciNova NASDAQ:MNOV$1.31 +0.02 (+1.55%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$1.30 -0.02 (-1.15%) As of 06/23/2025 04:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.Veru NASDAQ:VERU$0.62 0.00 (-0.50%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$0.60 -0.02 (-2.42%) As of 06/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
